Irma Bagdoniene: Statin Intolerance – Challenges and Solutions
Irma Bagdoniene, Cardiologist Specializing in Prevention & Lipidology, shared on LinkedIn:
“Statin intolerance: a frequent clinical challenge, but far from a dead end.
True, confirmed statin intolerance with myopathy and CK elevation occurs in about 5% of patients reporting symptoms. Many are actually experiencing the well-documented nocebo effect.
For us, this does not mean stopping therapy. It means adapting our approach.
Most patients labeled ‘intolerant’ do well after switching to another statin (for example, hydrophilic rosuvastatin) or trying low-dose, alternate-day dosing.
For those truly intolerant, therapeutic options remain robust and effective:
• Ezetimibe lowers LDL-C by 15–20%
• Bempedoic acid reduces LDL-C by 15–25% without muscle-related symptoms
• PCSK9 inhibitors provide a powerful 50–60% LDL-C reduction
• Inclisiran, with just twice-yearly dosing, delivers sustained ~60% LDL-C lowering
The CLEAR-Outcomes trial also highlighted that in statin-intolerant patients, hsCRP may predict cardiovascular risk even better than LDL-C.
The take-home message: stopping lipid-lowering therapy should be avoided wherever possible. Re-challenge, switch agents, or refer to a lipid specialist — but never leave high-risk patients unprotected. •
A highly recommended statement on this from the National Lipid Association.”
Stay with Hemostasis Today to explore more from Irma Bagdoniene.
-
Jun 23, 2026, 23:30Shunsuke Iwano: PMDA Introduces Greater Flexibility for Pediatric Factor VIII and IX Development in Japan
-
Jun 23, 2026, 23:05Rounak Dubey: ISBT Academy Session on Agentic AI
-
Jun 23, 2026, 22:59Mohammed Maher Babiker: When ‘Low Platelets’ aren’t Really Low
-
Jun 23, 2026, 22:49Giovanni Merlino: Why Does Stress Hyperglycemia Worsen Stroke Outcomes?
-
Jun 23, 2026, 22:41Tareq Abadl: Coombs Test – The Key to Detecting Immune-Mediated Hemolysis
-
Jun 23, 2026, 22:32How WFH Impacted the Bleeding Disorders Community in 2025
-
Jun 23, 2026, 22:03Erin VanDyke: A Journey Through VTE Leadership and Healthcare Transformation
-
Jun 23, 2026, 21:19Ahmed Koriesh: Join Us for Future of Stroke Care 2026
-
Jun 23, 2026, 20:30Aladdin Mohammad: Baseline IgG as a Key Predictor of Hypogammaglobulinaemia in AAV